Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAFAEL FONSECA

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1275517898
CMS profile
239212
Location
SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$123,193.24

65 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $22,519.28 13
GlaxoSmithKline, LLC. $17,800.00 2
Celgene Corporation $16,800.00 4
Janssen Biotech, Inc. $13,516.58 11
Amgen Inc. $11,628.00 6
Janssen Global Services, LLC $10,787.42 9
Karyopharm Therapeutics Inc. $7,248.03 2
Adaptive Biotechnologies Corporation $7,200.00 2
AstraZeneca UK Limited $6,850.00 2
PFIZER INC. $5,530.38 4
E.R. Squibb & Sons, L.L.C. $2,152.50 1
Dr.Reddy's Laboratories,Inc. $750.00 1
Gilead Sciences, Inc. $162.50 1
AstraZeneca Pharmaceuticals LP $125.00 3
ABBVIE INC. $123.55 4

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAFAEL FONSECA

NPI 1275517898 · CMS profile ID 239212

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275517898?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAFAEL FONSECA, NPI 1275517898, CMS profile ID 239212. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275517898?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RAFAEL FONSECA, NPI 1275517898, CMS profile ID 239212. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275517898?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RAFAEL FONSECA, NPI 1275517898, CMS profile ID 239212, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1275517898?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

65 matching records · $123,193.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 65 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–65 of 65.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $62.5306/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885515593 CMS
PFIZER INC. $115.9206/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949481241 CMS
GENZYME CORPORATION $150.0006/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938828989 CMS
PFIZER INC. $4,410.0005/30/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949354331 CMS
Janssen Global Services, LLC $1,860.0005/27/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887126459 CMS
AstraZeneca UK Limited $3,425.0005/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914974119 CMS
Amgen Inc. $649.0005/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939948493 CMS
Amgen Inc. $649.0004/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939948491 CMS
Adaptive Biotechnologies Corporation $4,000.0003/31/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951432595 CMS
Karyopharm Therapeutics Inc. $7,200.0003/18/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946526585 CMS
Janssen Biotech, Inc. $1,240.0003/16/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885515561 CMS
Amgen Inc. $2,280.0003/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939948489 CMS
GlaxoSmithKline, LLC. $2,600.0002/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944366053 CMS
AstraZeneca UK Limited $3,425.0002/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915822599 CMS
Celgene Corporation $7,800.0001/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932912841 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $69,124.14 53
PY2020 $98,566.31 43
PY2021 $110,395.08 49
PY2022 $123,193.24 65
PY2023 $104,178.66 49
PY2024 $69,113.38 41
PY2025 $75,923.86 34

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $179,962.74 18
PY2024 Recipient $2,650.44 5
PY2024 Principal investigator $240,375.22 21
PY2023 Principal investigator $459,074.73 29
PY2022 Recipient $1,270.00 2
PY2022 Principal investigator $169,296.59 8
PY2021 Recipient $1,351.65 1
PY2021 Principal investigator $356,932.10 9
PY2020 Principal investigator $155,064.22 7
PY2019 Recipient $4,001.12 2
PY2019 Principal investigator $229,698.90 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $2,050.00 11/21/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211549630
Principal investigator 1 Genentech, Inc. $28,729.70 10/15/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211549614
Principal investigator 1 PFIZER INC. $9,800.00 10/07/2025 Covered Recipient Teaching Hospital
MAYO CLINIC HOSPITAL
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228824518
Principal investigator 1 Alexion Pharmaceuticals, Inc. $6,300.00 10/02/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. No dispute reported 06/30/2026 1185545192
Principal investigator 1 Genentech, Inc. $4,461.30 08/27/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211549596
Principal investigator 1 Genentech, Inc. $1,524.80 08/22/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211549592
Principal investigator 1 Genentech, Inc. $1,161.80 08/22/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211549602
Principal investigator 1 Genentech, Inc. $6,037.00 08/22/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211549606
Principal investigator 1 Genentech, Inc. $3,050.60 08/22/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211549610
Principal investigator 1 Genentech, Inc. $16,239.60 06/06/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211549589
Principal investigator 1 Genentech, Inc. $6,900.00 06/03/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211549618
Principal investigator 1 Genentech, Inc. $10,173.00 04/25/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211549622
Principal investigator 1 Genentech, Inc. $10,830.00 04/25/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211549626
Principal investigator 1 Alexion Pharmaceuticals, Inc. $19,997.82 04/23/2025 Non-covered Recipient Entity
MAYO CLINIC CANCER CENTER
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. No dispute reported 06/30/2026 1185545197
Principal investigator 1 Genentech, Inc. $1,200.80 03/05/2025 Non-covered Recipient Entity
MAYO CLINIC ROCHESTER
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211622819
Principal investigator 1 Genentech, Inc. $9,101.60 03/05/2025 Non-covered Recipient Entity
MAYO CLINIC ROCHESTER
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211622825
Principal investigator 1 Alexion Pharmaceuticals, Inc. $42,104.72 01/08/2025 Non-covered Recipient Entity
MAYO CLINIC PEDIATRIC HEMATOLOGY ONCOLOGY
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. No dispute reported 06/30/2026 1185545195
Principal investigator 1 PFIZER INC. $300.00 01/07/2025 Covered Recipient Teaching Hospital
MAYO CLINIC HOSPITAL
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228831492